Tumaini Trial to Test Ervebo Cross-Protection Against Bundibugyo Ebola in DRC

The trial addresses a critical gap: Ervebo received regulatory approval solely for the Zaire strain after the 2014-2016 West African epidemic, yet the current DRC outbreak is driven by Bundibugyo. WHO SAGE members noted that existing immunogenicity data suggesting possible cross-protection remain insufficient for policy without a controlled efficacy study. The single-trial platform will initially test Ervebo while preparing to incorporate two Bundibugyo-specific candidates from Oxford and Moderna once early-phase safety and immunogenicity results are reviewed.

Ongoing insecurity and population displacement have already delayed surveillance and care delivery, limiting the ability to conduct randomized assessments. Doctors Without Borders is administering Ervebo to frontline workers as an interim measure outside the formal trial, generating observational data that will require careful adjustment for confounding before any causal inference. Historical patterns from the 2018-2020 Équateur and North Kivu outbreaks show that ring vaccination succeeded only when access remained stable.

Next steps hinge on the technical advisory group's review of small-scale trial data; if reassuring, Oxford's ChAdOx1 vector vaccine could enter Tumaini within months. Regulators will need at least 6-12 months of follow-up to establish whether any observed protection meets the threshold for strain-specific recommendations.